Abstract: The present invention relates to the use of hydroxymethyl group donors, in particular of hyaluronic acid which contains hydroxymethyl groups, for treating and preventing an infection by enveloped viruses such as coronaviruses, paramyxoviruses, e.g. RS viruses, or orthomyxoviruses, such as influenza viruses, and/or for treating or preventing an inflammatory disease of the respiratory tract, for example COPD, ARDS or cystic fibrosis, in particular an inflammatory disease of the respiratory tract associated with a viral infection.

Abstract: The present invention relates to the use of hydroxymethyl-group-containing glycosaminoglycans, such as in particular hydroxymethyl-hyaluronic acid, for the treatment and prevention of infectious diseases or malignant or premalignant diseases, in particular of the skin or mucosa. The invention additionally provides a preparation method for glycosaminoglycans modified with hydroxymethyl groups.

Abstract: The present invention relates to the use of hydroxymethyl-group-containing glycosaminoglycans, such as in particular hydroxymethyl-hyaluronic acid, for the treatment and prevention of infectious diseases or malignant or premalignant diseases, in particular of the skin or mucosa. The invention additionally provides a preparation method for glycosaminoglycans modified with hydroxymethyl groups.

Abstract: The present invention relates to the use of hyaluronic acid for treating inflammatory diseases, in particular skin or mucous membrane diseases.

Abstract: The present invention relates to the use of hyaluronic acid for treating inflammatory diseases, in particular skin or mucous membrane diseases.

Abstract: The invention relates to novel applications of pharmaceutical compositions containing preferably long-chain hyaluronic acids which are cross-linked or not cross-linked, and conventional adjuvants and/or supporting materials.

Abstract: The present invention relates to an implantable device for valuables.

Abstract: The present invention relates to the use of hyaluronic acid for treating inflammatory diseases, in particular skin or mucous membrane diseases.

Abstract: The invention relates to novel applications of pharmaceutical compositions containing preferably long-chain hyaluronic acids which are cross-linked or not cross-linked, and conventional adjuvants and/or supporting materials.

Abstract: The invention relates to a device for transdermally exerting a defined pressure on subcutaneous tissue, especially where cellulite is present, said device being intended to produce a jet pressure in the range of 1 to 20 bar, so that no mechanical contact is necessary between the device and the skin, and said device having at least one nozzle for a fluid medium. The invention also relates to a cosmetic method for smoothing out cellulite by exerting regional, especially sub-regional, transdermal pressure on an area of skin to be treated with 1 to 50 kg per cm2 of skin and, if appropriate, by repeating this process at least once.

Abstract: An implant for medical purposes based on a physiologically compatible plastic is composed of thin foldable structural elements having a surface that can be wetted by a fluid lubricant and is preferably surrounded by a covering that contains a lubricant such as e.g. an aqueous fluid.

Abstract: A method and a pharmaceutical composition for non-topical wound, scar and keloid treatment is described which contains cross-linked glycosaminoglycans and conventional pharmaceutical auxiliary and/or carrier substances. The pharmaceutical composition is preferably administered intralesionally e.g. by injection in the form of a gel containing water. The cross-linked glycosaminoglycans are also suitable for use as cosmetics and skin care products.

Abstract: Taurolin compounds are used as blood coagulation-inhibiting agents and as abacterial inflammation-inhibiting agents. The outstanding coagulation-inhibiting action of taurolin is especially suitable for use in medical conditions requiring dialysis and for vascular protheses. These compounds can also be used together with other anti-coagulants such as coumarin or heparin.

Abstract: A device for inserting in wounds and wound cavities is described consisting of a container containing a pharmaceutical active substance, the walls of this container consisting at least partly of a membrane, preferably a semi-permeable membrane, which allows the active substance to escape into the wound area. The container is, more preferably, a dialysis tube. In order to drain off wound secretions, the container containing the pharmaceutically active substance, particularly taurolidine, is conveniently connected to a drainage tube. Preferably, a drainage tube is used in which the end which leads into the wound is split into filaments.

Abstract: Plastic implant, particularly for use in implantations for constructing or reconstructing the female breast, wherein the surface of the impant is covered over with heparin.